Commentary on the clinical trial reported by: Tewari KS, Sill M, Long III HJ, et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. J Clin Oncol 2013;(suppl; abstr 3)

Michael L. Friedlander

Abstract

One of the highlights of the recent ASCO meeting was the presentation of the results of GOG 240 by Tewari on behalf of his co-investigators in a plenary session (1). This was a positive trial which reported a significant increase in overall survival (OS) of women with metastatic/recurrent cervical cancer who were treated with bevacizumab in combination with chemotherapy. This is likely to change the standard of care of women with recurrent/metastatic cervical cancer in well-resourced regions of the world in particular and deserves review and detailed discussion.